C Aass1,2, I Norheim3, E F Eriksen4,3, E C Børnick5, P M Thorsby6, M Pepaj6. 1. Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway. cecilaas@medisin.uio.no. 2. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. cecilaas@medisin.uio.no. 3. Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway. 4. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 5. University Department of Ophthalmology, Oslo University Hospital, Oslo, Norway. 6. Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: Graves' orbitopathy (GO) is a severe organ-specific autoimmune inflammatory ocular complication most often associated with Graves' disease (GD). Besides the cosmetic problems these patients develop, GO may also cause severe, sight-threatening complications. Additionally, GO complicates the treatment of patients with GD, making the identification of Graves patients at risk for eye disease before they develop symptoms a critical step in the clinical management and quality of life of these patients. The high concentration of proteins in tear fluid makes it an important source for studying potential protein biomarkers for GO. PATIENTS AND METHODS: The aim of this study was to quantitatively compare tear fluid from GD patients with moderate/severe GO (GO) and patients with GD without GO (controls) using untargeted quantitative proteomics based on dimethyl labelling in combination with two-dimensional liquid chromatography-mass spectrometry. RESULTS: Among the 1212 proteins identified, 16 showed significant alterations in abundance between the two groups. Thus, in this study, we reveal a number of novel dysregulated proteins in GO which may contribute to a better understanding of the disease. In particular, upregulation of lacrimal gland proteins such as lysozyme C, lacritin, antileukoproteinase and zinc-alpha-2-glycoprotein 1 suggests involvement of the lacrimal gland in the pathogenesis of GO. CONCLUSIONS: It remains to be elucidated whether some of these proteins can be used as markers for patients at risk for developing GO as well as useful indicators for disease activity.
BACKGROUND:Graves' orbitopathy (GO) is a severe organ-specific autoimmune inflammatory ocular complication most often associated with Graves' disease (GD). Besides the cosmetic problems these patients develop, GO may also cause severe, sight-threatening complications. Additionally, GO complicates the treatment of patients with GD, making the identification of Graves patients at risk for eye disease before they develop symptoms a critical step in the clinical management and quality of life of these patients. The high concentration of proteins in tear fluid makes it an important source for studying potential protein biomarkers for GO. PATIENTS AND METHODS: The aim of this study was to quantitatively compare tear fluid from GDpatients with moderate/severe GO (GO) and patients with GD without GO (controls) using untargeted quantitative proteomics based on dimethyl labelling in combination with two-dimensional liquid chromatography-mass spectrometry. RESULTS: Among the 1212 proteins identified, 16 showed significant alterations in abundance between the two groups. Thus, in this study, we reveal a number of novel dysregulated proteins in GO which may contribute to a better understanding of the disease. In particular, upregulation of lacrimal gland proteins such as lysozyme C, lacritin, antileukoproteinase and zinc-alpha-2-glycoprotein 1 suggests involvement of the lacrimal gland in the pathogenesis of GO. CONCLUSIONS: It remains to be elucidated whether some of these proteins can be used as markers for patients at risk for developing GO as well as useful indicators for disease activity.
Authors: Hadi Khazaei; Danesh Khazaei; Rohan Verma; John Ng; Phillip A Wilmarth; Larry L David; James T Rosenbaum Journal: Exp Eye Res Date: 2021-11-03 Impact factor: 3.467
Authors: Cecilie Aass; Ingrid Norheim; Erik Fink Eriksen; Ellen Charlotte Børnick; Per Medbøe Thorsby; Milaim Pepaj Journal: PLoS One Date: 2017-04-18 Impact factor: 3.240
Authors: Sheila T Angeles-Han; Steven Yeh; Purnima Patel; Duc Duong; Kirsten Jenkins; Kelly A Rouster-Stevens; Mekibib Altaye; Ndate Fall; Sherry Thornton; Sampath Prahalad; Gary N Holland Journal: J Ophthalmic Inflamm Infect Date: 2018-10-16